[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardioprotection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardioprotection":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100572600","exercise-preconditioning-to-protect-against-dialysis-induced-cardiac-injury-100572600",false,"NCT06735378","Exercise Preconditioning to Protect Against Dialysis-induced Cardiac Injury","Exercise Preconditioning to Protect Against Dialysis-induced Cardiac Injury in Hemodialysis Patients: a Randomized Controlled Trial","Inclusion Criteria:\n\n* must be on chronic hemodialysis for at least 3 months\n* age 18 years or older\n* willing and able to provide informed consent\n* assessed to be safe and able to exercise by unit HD Nephrologist\n\nExclusion Criteria:\n\n* regular vigorous exercise outside of hemodialysis\n* over 79 years of age\n* intradialytic exercise \\\u003C 3 months\n* poor echogenicity\n* acute coronary syndrome in the past 3 months\n* unstable arrhythmia\u002Fangina\n* shortness of breath at rest or with minimal activity\n* symptomatic hypoglycemia (\\>2x\u002Fweek in the week prior to enrolment)","ALL","18 Years","79 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this study is to determine what happens to the heart muscle contraction when people cycle before their hemodialysis treatment. Will pre-dialysis exercise protect the heart from a decrease in pumping of the heart muscle (called stunning) that can happen during hemodialysis. We will study whether pre-dialysis exercise decreases heart stunning, decreases the number and severity of symptoms commonly associated with hemodialysis, and other outcomes",[27,28],"Hemodialysis","Cardioprotection",[28,30,27],"Preconditioning Exercise","RECRUITING","2025-01-20",{"date":34,"type":35},"2025-01-22","ACTUAL",{"date":32,"type":35},{"date":38,"type":21},"2025-12-31",{"name":40,"class":41},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100432546","cardioprotective-effect-of-dexmedetomidine-in-patients-with-st-segment-elevation-myocardial-infarction-100432546","NCT04912518","Cardioprotective Effect of Dexmedetomidine in Patients With ST-segment Elevation Myocardial Infarction","Cardioprotective Effect of Dexmedetomidine in Patients With ST-segment Elevation Myocardial Infarction: a Double-Blind, Multicenter, Randomized, Placebo-Controlled Clinical Trial","COOPERATION","Inclusion Criteria: the enrolled subjects must meet all of the following criteria:\n\n* Aged 18-75 years old (inclusive);\n* Diagnosed with anterior STEMI within 6h of symptom onset: (1) ischemic chest discomfort; (2) electrocardiogram (ECG) with ST elevation ≥0.2 mV in 2 or more contiguous precordial leads (one of which should be V2, V3, or V4);\n* Sign the informed consent form.\n\nExclusion Criteria: subjects who meet any one of the following criteria are excluded from the study:\n\n* Ventricular fibrillation, cardiogenic shock, Killip III-IV grade;\n* Sinus bradycardia (heart rate sustained \\\u003C60 beats\u002Fmin), PR interval\\> 240ms or II-III degree atrioventricular block;\n* Continuous systolic blood pressure \\\u003C120mmHg;\n* Severe breathing difficulties, aterial blood oxygen saturation \\\u003C92%;\n* Thrombolytic therapy has been performed before the first medical contact in the hospital;\n* Consciousness disorder or past cerebrovascular disease;\n* Previous history of myocardial infarction or PCI\u002FCABG treatment;\n* Known severe liver and kidney dysfunction;\n* Known allergy to dexmedetomidine;\n* CMR contraindications: such as claustrophobia, pacemaker or ICD implantation;\n* Pregnant or lactating women;\n* Malignant tumor or expected survival time \\\u003C1 year;\n* Any condition which in the opinion of the investigator would make it unsafe or unsuitable for the patient to participate in this study (eg, poor compliance, inability of the patient to comply with study procedures and\u002For follow up);\n* Participate in other randomized controlled studies at the same time.","75 Years",{"count":53,"type":21},250,[24],"This is a double-blind, multicenter, randomized, placebo-controlled clinical trial. It is planned to enroll patients admitted with anterior ST-segment elevation myocardial infarction (STEMI) within 6h of symptom onset and undergo primary percutaneous coronary intervention (pPCI). Patients who meet the inclusion criteria and without exclusion criteria were randomized 1:1 into the dexmedetomidine (DEX) group or the placebo (saline) group after signing the informed consent. In the DEX group, intravenous injection of DEX was started immediately after enrollment, covering the entire PCI operation, and the administration was stopped at the end of the pPCI. The administration of saline was the same as those in the DEX group. The primary endpoint was the myocardial infarct size (MIS) as assessed by cardiac magnetic resonance imaging (CMR) at 5±2 days post-STEMI. Based on a superiority design and assuming an 20.0% relative infarct size reduction (from 26.0% to 20.8% with a SD of 13.0%), 250 patients are required to be enrolled, accounting for 20% drop-out (α= 0.05 and power= 80%).",[57,58,28],"ST-segment Elevation Myocardial Infarction (STEMI)","Percutaneous Coronary Intervention",[57,60,61,28],"Percutaneous coronary intervention","Dexmedetomidine","2024-10-11",{"date":64,"type":35},"2024-10-15",{"date":66,"type":35},"2021-05-27",{"date":68,"type":21},"2025-12",{"name":70,"class":41},"Harbin Medical University",9]